penses
Selling, general and administrative 11,885,368 8,339,227
Research and development 993,069 -
Goodwill impairment - 200,000
Total operating expenses 12,878,437 8,539,227
Operating (loss) income (1,274,022) 1,113,161
Other expense (income)
Interest expense 413,992 374,079
Loss on debt extinguishment 256,628 -
Other expense (income) 77,929 (47,998)
Total other expense 748,549 326,081
(Loss) income before provision for income taxes (2,022,571) 787,080
Provision for income taxes 262,034 118,341
Net (Loss) Income $(2,284,605) $668,739
(Loss) income per common share - basic and
diluted $(0.09) $0.03
Shares used in computing (loss) income per
common share - basic 26,523,541 20,591,085
Shares used in computing (loss) income per
common share - diluted 26,523,541 24,409,760
'/>"/>SOURCE Derma Sciences Inc Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related biology technology :1.
Actavis Receives Approval of Fentanyl Transdermal System in the U.S.2.
Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds3.
AGI Dermatics President to be Keynote Speaker at the 11th Annual Sunscreen Symposium4.
Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines5.
Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema6.
Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis7.
Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results8.
Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 20089.
AGI Dermatics Clinical Data Identifies L-Ergothioneine as Part of Skins Natural Antioxidant System10.
Lucid Launches VivaNet(R) Telemedicine Server for Dermatology Applications11.
JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis